Follow The Filings

RANI Rani Therapeutics

Rani Therapeutics earnings company data as of 10:00 AM ET 10/23

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

History

2 periods, newest first. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 5 Nov EPS — — —
Rev — — —
FY2026 Q2 13 Aug EPS — — —
Rev — $1.7M —

Insider trades

Open-market buys and sales by RANI's executives, directors and 10% owners in the last 12 months, from their Form 4s

All RANI insider trades
  • $1.3M bought by 2 insiders
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Mir A Imran Director
    Buy
    $25K 36,000 shares at $0.6900 +1.7% to stake
    Traded Jul 21 Filed Jul 23
  2. Talat Imran CEO
    Buy
    $25K 35,000 shares at $0.7200 +8.1% to stake
    Traded Jul 17 Filed Jul 21
  3. Mir A Imran Director
    Buy
    $1.3M 2,083,334 shares at $0.6100 New stake
    Traded Oct 23, 2025 Filed Oct 27, 2025
  4. South Cone Investments Limited Partnership 10% owner
    Sale
    $15.7M 5,923,000 shares at $2.65 71% of stake
    Traded Oct 20–21 Filed Oct 22, 2025

Also filed in the last 12 months, not counted as buying or selling: 7 share withholdings for taxes and 1 sale to cover taxes.

SEC filings

Recent issuer filings from EDGAR, 23 shown.

Filed Form Detail Links
SCHEDULE 13G/A —
8-K 2.02,9.01
10-Q
8-K 5.02
SCHEDULE 13G/A —
8-K 5.02,9.01
8-K 5.07
SCHEDULE 13D/A —
424B5
8-K 8.01,9.01
SCHEDULE 13G/A —
8-K 2.02,3.01,5.02,9.01
10-Q
SCHEDULE 13G —
DEF 14A
DEFA14A DEFA 14A
SCHEDULE 13G/A —
8-K 2.02,9.01
10-K
SCHEDULE 13G —
SCHEDULE 13G —
SCHEDULE 13G —
8-K 1.02,3.03,5.03,5.07,9.01

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.